Amtagvi Traction Is Real, but Volatility Ahead - Iovance Is a Tactical Buy for Patients
Iovance ($IOVA) is a commercially approved TIL (tumor-infiltrating lymphocyte) company whose lifileucel (Amtagvi) is generating real-world response rates above trial expectations. The stock is technically extended and has material short interest, so expect pullbacks. For disciplined traders, a controlled long entry around $4.12 with a $3.30 stop an…